Binghong Xu

5PUBLICATIONS
26CO-AUTHORS
Medical devicesNanotoxicology, health and safetyMolecular targetsMajor global burdens of diseaseBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 11, 2025
Structure-guided screening identifies Tucatinib as dual inhibitor for MCT1/2.

Binghong Xu, Xiaoyu Zhou, Yuanyue Shan

|Nov 19, 2025
A rationally designed cocktail of nanobodies elicited by heterologous vaccination confers protection against SFTSV in preclinical models.

Xilin Wu, Linjing Zhu, Shengjian Liang

|Jun 05, 2025
Bardoxolone methyl blocks the efflux of Zn2+ by targeting hZnT1 to inhibit the proliferation and metastasis of cervical cancer.

Yaxin Wang, Qinqin Liang, Shengjian Liang

|Nov 18, 2024
Etoposide targets 2A protease to inhibit enterovirus 71 replication.

Qinqin Liang, Sai Shi, Qingjie Zhang

|Feb 26, 2022
Discovery of SARS-CoV-2 3CLPro Peptidomimetic Inhibitors through the Catalytic Dyad Histidine-Specific Protein-Ligand Interactions.

Yaxin Wang, Binghong Xu, Sen Ma

Pageof 1

Frequent Collaborators

4 joint publications

Sheng Ye

4 joint publications

Yaxin Wang

2 joint publications

Shengjian Liang

2 joint publications

Zhiyong Lou